Resolvin E1 derived from eicosapentaenoic acid prevents hyperinsulinemia and hyperglycemia in a host genetic manner

Eicosapentaenoic acid (EPA) has garnered attention after the success of the REDUCE‐IT trial, which contradicted previous conclusions on EPA for cardiovascular disease risk. Here we first investigated EPA's preventative role on hyperglycemia and hyperinsulinemia. EPA ethyl esters prevented obesi...

Descripción completa

Detalles Bibliográficos
Autores principales: Pal, Anandita, Al‐Shaer, Abrar E., Guesdon, William, Torres, Maria J., Armstrong, Michael, Quinn, Kevin, Davis, Traci, Reisdorph, Nichole, Neufer, P. Darrell, Spangenburg, Espen E., Carroll, Ian, Bazinet, Richard P., Halade, Ganesh V., Clària, Joan, Shaikh, Saame Raza
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7497168/
https://www.ncbi.nlm.nih.gov/pubmed/32579292
http://dx.doi.org/10.1096/fj.202000830R

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7497168/
https://www.ncbi.nlm.nih.gov/pubmed/32579292
http://dx.doi.org/10.1096/fj.202000830R

Ejemplares similares